Jeffrey K Huang

Summary

Affiliation: University of Cambridge
Country: UK

Publications

  1. ncbi Regenerative medicine in multiple sclerosis: identifying pharmacological targets of adult neural stem cell differentiation
    Jeffrey K Huang
    MRC Centre for Stem Cell Biology and Regenerative Medicine and Department of Veterinary Medicine, University of Cambridge, Cambridge, UK
    Neurochem Int 59:329-32. 2011
  2. ncbi BDNF promotes target innervation of Xenopus mandibular trigeminal axons in vivo
    Jeffrey K Huang
    Wellcome Trust Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge, UK
    BMC Dev Biol 7:59. 2007
  3. ncbi Myelin regeneration in multiple sclerosis: targeting endogenous stem cells
    Jeffrey K Huang
    MRC Cambridge Centre for Stem Cell Biology and Regenerative Medicine, and Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge, United Kingdom
    Neurotherapeutics 8:650-8. 2011
  4. ncbi Accelerated axonal loss following acute CNS demyelination in mice lacking protein tyrosine phosphatase receptor type Z
    Jeffrey K Huang
    Wellcome Trust and MRC Cambridge Stem Cell Institute, University of Cambridge, United Kingdom
    Am J Pathol 181:1518-23. 2012
  5. ncbi Retinoid X receptor gamma signaling accelerates CNS remyelination
    Jeffrey K Huang
    MRC Centre for Stem Cell Biology and Regenerative Medicine and Department of Veterinary Medicine, University of Cambridge, Cambridge, UK
    Nat Neurosci 14:45-53. 2011
  6. ncbi Current status of myelin replacement therapies in multiple sclerosis
    Jeffrey K Huang
    Wellcome Trust and MRC, Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
    Prog Brain Res 201:219-31. 2012

Detail Information

Publications6

  1. ncbi Regenerative medicine in multiple sclerosis: identifying pharmacological targets of adult neural stem cell differentiation
    Jeffrey K Huang
    MRC Centre for Stem Cell Biology and Regenerative Medicine and Department of Veterinary Medicine, University of Cambridge, Cambridge, UK
    Neurochem Int 59:329-32. 2011
    ..We discuss the role of LINGO-1, Notch, Wnt, and retinoid X receptor (RXR) signaling, and how they might be useful pharmacological targets to overcoming remyelination failure in MS...
  2. ncbi BDNF promotes target innervation of Xenopus mandibular trigeminal axons in vivo
    Jeffrey K Huang
    Wellcome Trust Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge, UK
    BMC Dev Biol 7:59. 2007
    ..Brain derived neurotrophic factor, BDNF is known to stimulate axon outgrowth and branching. The goal of this study is to determine whether BDNF functions as the proposed target recognition signal in the Xenopus cement gland...
  3. ncbi Myelin regeneration in multiple sclerosis: targeting endogenous stem cells
    Jeffrey K Huang
    MRC Cambridge Centre for Stem Cell Biology and Regenerative Medicine, and Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge, United Kingdom
    Neurotherapeutics 8:650-8. 2011
    ..We highlight recent studies on factors that influence endogenous remyelination and potential promising pharmacological targets that may be considered for enhancing central nervous system remyelination...
  4. ncbi Accelerated axonal loss following acute CNS demyelination in mice lacking protein tyrosine phosphatase receptor type Z
    Jeffrey K Huang
    Wellcome Trust and MRC Cambridge Stem Cell Institute, University of Cambridge, United Kingdom
    Am J Pathol 181:1518-23. 2012
    ....
  5. ncbi Retinoid X receptor gamma signaling accelerates CNS remyelination
    Jeffrey K Huang
    MRC Centre for Stem Cell Biology and Regenerative Medicine and Department of Veterinary Medicine, University of Cambridge, Cambridge, UK
    Nat Neurosci 14:45-53. 2011
    ..Our results indicate that RXR-γ is a positive regulator of endogenous oligodendrocyte precursor cell differentiation and remyelination and might be a pharmacological target for regenerative therapy in the CNS...
  6. ncbi Current status of myelin replacement therapies in multiple sclerosis
    Jeffrey K Huang
    Wellcome Trust and MRC, Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
    Prog Brain Res 201:219-31. 2012
    ..In this chapter, in addition to describing why remyelination therapies are important, we review both these approaches, outlining their current status and future developments...